Abbott (ABT.US) Q3 revenue beats expectations but full-year guidance lowered; nutrition business plans to be spun off and listed.

Zhitong Finance APP has learned that Abbott Laboratories (ABT.US) reported third-quarter 2026 results on Wednesday, showing that quarterly sales rose 15% year-over-year to $13.01 billion, above the market expectation of $12.99 billion; adjusted earnings per share were $1.42, up 9% year-over-year and in line with market expectations; gross margin rose to approximately 57% from about 56% in the same period last year.